Beyond Air, Inc. (XAIR)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 1 | 0 | 0 | 1 | 4 | 8 | 8 |
| Operating profit | $m | -29 | -28 | ||||||
| Net profit | $m | -20 | -23 | -43 | -56 | -60 | -47 | -33 | -33 |
| EPS reported | $ | -80.20 | -53.60 | ||||||
| Operating cashflow per share | $ | -2.19 | -43.72 | ||||||
| Capex per share | $ | 0.12 | 2.47 | ||||||
| FCF per share | $ | -2.31 | -46.19 | ||||||
| Free cash flow | $m | -19 | -20 | ||||||
| Net debt | $m | 10 | -8 | ||||||
| Book value equity | $m | 6 | 2 | ||||||
| Book value per share | $ | 14.76 | 2.77 | ||||||
| Number of shares | m | 0.42 | 0.72 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 18.70 | 9.24 | ||||||
| P/S LTM | x | 0.24 | 2.40 | ||||||
| P/FCF LTM | x | -5.98 | -0.94 | ||||||
| EV/EBITDA LTM | x | -4.83 | -0.82 | ||||||
| EV/Sales LTM | x | 15.31 | 2.66 | ||||||
| Earnings Yield LTM | % | -29.03% | -15.33% | ||||||
| FCF Yield | % | -16.73% | -106.23% | ||||||
| Quality | |||||||||
| ROE | % | -542.75% | -360.45% | ||||||
| ROIC | % | -98.13% | -98.13% | ||||||
| Operating margin | % | -3.78% | -3.78% | ||||||
| Gross margin | % | +3.28% | +3.28% | ||||||
| FCF/Sales | % | -249.63% | -249.63% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +107.26% | +563.24% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.82 | -8.14 | ||||||
| Net Debt/EBITDA | x | -0.53 | -0.66 | ||||||
| EBIT/Net interest | x | 0.00 | -8.26 | ||||||
| Net debt/market cap | % | +19.24% | +5.85% | ||||||
| Net debt/Equity | x | 1.70 | -4.20 | ||||||
| Gross debt/equity | x | 3.82 | 1.21 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free